A CHECKLIST FOR SUITABILITY OF BIOMARKERS AS SURROGATE END-POINTS IN CHEMOPREVENTION OF BREAST-CANCER

被引：0
|
作者：
BOGOCH, S
BOGOCH, ES
机构：
[1] BOSTON UNIV, SCH MED, BOSTON, MA 02215 USA
[2] ONCOLAB, BOSTON, MA 02215 USA
来源：
JOURNAL OF CELLULAR BIOCHEMISTRY | 1994年
关键词：
ANTIMALIGNIN; CANCER ANTIBODY; CANCER ANTIGEN; CANCER VACCINE; CYTOTOXICITY; GLYCOPROTEINS; IMMUNOSURVEILLANCE; MALIGNIN;
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
By reference to a ''checklist'' of requirements for substances or processes to qualify as surrogate endpoint biomarkers, both malignin and antimalignin antibody are found to be suitable for use in breast cancer chemoprevention trials. Antimalignin has been shown to be highly specific and sensitive, modulatable and reversible, detectable early in appearance of malignancy and upon recovery therefrom, and differentially expressed in high-risk individuals as compared with the general population. (C) 1994 Wiley-Liss, Inc.
引用
收藏
页码：173 / 185
页数：13
相关论文
共 50 条
  • [41] ONCOGENES, BREAST-CANCER, AND CHEMOPREVENTION
    LIU, ET
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 161 - 166
  • [42] CHEMOPREVENTION OF BREAST-CANCER WITH TAMOXIFEN
    NAMER, M
    SERIN, D
    PATHOLOGIE BIOLOGIE, 1994, 42 (01): : 28 - 29
  • [43] BENIGN BREAST DISEASE - END-POINTS OF TREATMENT
    FORREST, AP
    CANCER DETECTION AND PREVENTION, 1992, 16 (01): : 61 - 65
  • [44] Problems with using biomarkers as surrogate end points for cancer: A cautionary tale
    Schatzkin, A
    TUMOR PREVENTION AND GENETICS III, 2005, 166 : 89 - 98
  • [45] SURROGATE END-POINT BIOMARKERS FOR PHASE-II CANCER CHEMOPREVENTION TRIALS
    KELLOFF, GJ
    BOONE, CW
    CROWELL, JA
    STEELE, VE
    LUBET, R
    DOODY, LA
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1994, : 1 - 9
  • [46] Prognostic biomarkers and surrogate end points in PSC
    Vesterhus, Mette
    Melum, Espen
    LIVER INTERNATIONAL, 2016, 36 (12) : 1748 - 1751
  • [47] DNA FLOW-CYTOMETRY MEASUREMENTS AS SURROGATE END-POINTS IN CHEMOPREVENTION TRIALS - CLINICAL, BIOLOGICAL, AND QUALITY-CONTROL CONSIDERATIONS
    DRESSLER, LG
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 212 - 218
  • [48] CHEMOPREVENTION TRIALS AND SURROGATE END-POINT BIOMARKERS IN THE CERVIX
    MITCHELL, MF
    HITTELMAN, WK
    LOTAN, R
    NISHIOKA, K
    TORTOLEROLUNA, G
    RICHARDSKORTUM, R
    WHARTON, JT
    HONG, WK
    CANCER, 1995, 76 (10) : 1956 - 1977
  • [49] SURROGATE AND AUXILIARY END-POINTS IN CLINICAL-TRIALS, WITH POTENTIAL APPLICATIONS IN CANCER AND AIDS RESEARCH
    FLEMING, TR
    PRENTICE, RL
    PEPE, MS
    GLIDDEN, D
    STATISTICS IN MEDICINE, 1994, 13 (09) : 955 - 968
  • [50] SURROGATE END-POINTS - THE CASE OF TRIALS ON CORONARY ATHEROSCLEROTIC PLAQUE REGRESSION
    MARCHIOLI, R
    PRIETO, JC
    TOGNONI, G
    CLINICAL TRIALS AND META-ANALYSIS, 1994, 29 (2-3) : 139 - 176
12345